8-K: Medicus Pharma Terminates Equity Purchase Agreement

Medicus Pharma Ltd. has mutually agreed with YA II PN, LTD. (Yorkville) to terminate their Standby Equity Purchase Agreement, effective September 11, 2026, with no outstanding borrowings or fees.

Summary

• Medicus Pharma Ltd. and YA II PN, LTD. (Yorkville) have mutually terminated their Standby Equity Purchase Agreement (SEPA) as of September 11, 2026.
• The SEPA allowed Medicus Pharma to issue and sell up to $15.0 million of its common shares to Yorkville.
• At the time of termination, there were no outstanding borrowings, advance notices, or common shares to be issued under the SEPA.
• No fees are due by either party in connection with this termination.
• Yorkville Securities, LLC, an affiliate of Yorkville, continues to act as a sales agent under a separate Equity Distribution Agreement dated December 29, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative development due to the termination of a potential financing agreement, although no funds were drawn. The lack of outstanding borrowings or fees mitigates immediate negative impact.

Positives

• The termination of the SEPA occurred mutually, indicating agreement between both parties.
• No funds were drawn under the SEPA, meaning no dilution or capital was raised through this specific agreement.
• There are no outstanding borrowings or advance notices related to the SEPA at the time of termination.
• No termination fees are owed by either Medicus Pharma or Yorkville.

Negatives

• The termination of a potential $15.0 million equity financing facility removes a source of future capital for the company.
• This action may signal a lack of immediate need for capital through this specific mechanism, or a change in financing strategy.

Risks

• The company may face challenges in securing future funding if alternative sources are not readily available or are less favorable.
• The termination could be interpreted by the market as a sign of financial uncertainty or a lack of confidence in the company's immediate capital needs via this route.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding future financing strategies or operational outlook beyond the termination of the SEPA.

Management Comments

• The Company and Yorkville mutually agreed to terminate the Standby Equity Purchase Agreement.
• At the time of termination, there were no outstanding borrowings, advance notices or Common Shares to be issued under the SEPA.
• There are no fees due by the Company or Yorkville in connection with the termination of the SEPA.

Industry Context

StockSavvy.ai notes that the termination of standby equity purchase agreements is not uncommon, especially if a company's financing needs or market conditions change. However, it removes a flexible, albeit potentially dilutive, source of capital that many smaller or growth-stage companies utilize.

Related Party Transactions

• Yorkville Securities, LLC, an affiliate of YA II PN, LTD. (Yorkville), remains a sales agent under the Company's Equity Distribution Agreement dated December 29, 2025 (as amended).

Stakeholder Impact

• Shareholders: The termination removes a potential source of capital that could have led to dilution, but also removes a potential funding mechanism for growth initiatives.
• Creditors: No immediate impact as no funds were drawn and no fees are due.
• Management: May need to explore alternative financing strategies to meet future capital requirements.

Next Steps

• Medicus Pharma Ltd. will need to rely on other existing or new financing arrangements to fund its operations and strategic initiatives.
• The company will continue to work with Yorkville Securities, LLC under the existing Equity Distribution Agreement.

Key Dates

Keywords

Equity Purchase Agreement, Financing, Capital Raise, Termination, Securities, Common Shares, Sales Agent